Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...